Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)

Trial Profile

Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Exemestane (Primary) ; Cyclophosphamide; Docetaxel
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 11 Feb 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 16 Nov 2014 Planned number of patients changed from 70 to 85, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top